“The accelerated approval of Rezdiffra represents a historic moment for the NASH field,” said Bill Sibold, CEO of Madrigal. “This signifies the best of what our industry is capable of.

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced the U.S. availability of Rezdiffra (resmetirom), marking a milestone in the treatment of non-alcoholic ...

By the end of last year, more than 11,800 patients were on Rezdiffra. In a conference call on Wednesday, Madrigal CEO Bill Sibold called the progress “an incredible accomplishment in just nine ...